A New UCLA study shows Ceremed Inc.'s Ostene, designed to stop bone bleeding during cardiac surgery, doesn't inhibit bone regeneration and is an effective substitute for commonly used bone wax, a beeswax-based remedy known to obstruct healing that has been in use at least since the Civil War and is a factor in hospital-acquired infections. The study results were announced at a scientific conference in Stockholm and will be published later this year.

Scientists at the University of California, Los Angeles compared the effect of Ostene and beeswax on the bone healing in rats. The results show that while the two materials are equally effective in stopping bone bleeding in surgery, the bone heals significantly quicker when treated with Ostene. "The signs of healing were visible as early as three weeks after surgery in the group treated with Ostene, while they were practically absent as late as twelve weeks after treatment in the beeswax group. That's a significant difference", says Ceremed's Senior Scientific Officer Jon Armstrong. Beeswax is currently the most widely used bone hemostasis material.

The UCLA study concluded that, unlike beeswax, Ostene does not inhibit bone healing and bone regeneration. The use of Ostene in cardiac surgery may therefore help reduce the risk of post-operative separation of the sternum — a serious and potentially lethal complication which affects one out of twenty cardiac surgery patients and is the result of the cut bone's failure to heal and hold together.

Ostene was invented as a long-overdue synthetic alternative to beeswax by scientists from the University of Southern California. They teamed up with Dr. Tad Wellisz, a USC clinical professor of surgery with experience in developing and marketing medical products, and gained FDA approval for Ostene last year. "I've spent 15 years in reconstructive surgery taking care of people with beeswax infections. I had a near-tragedy in my own family that can be directly attributed to the use of beeswax. When I learned of an alternative, I knew that bringing it into clinical use was something I had to do", explains Ceremed's CEO Dr. Tad Wellisz. "With the current emergence of antibiotic-resistant bacteria, we absolutely have to do all we can to reduce the risk of hospital-acquired infections."

Research supports Dr. Wellisz's experience with beeswax. Beeswax increases the risk of infection, causes inflammation, swelling and debilitating pain. It is a factor in hospital-acquired antibiotic-resistant infections — according to a study in the Journal of Thoracic and Cardiovascular Surgery, the presence of beeswax reduces the number of bacteria needed to produce a bone infection by a factor of 10,000. Another study, published in the April 2006 issue of the journal Pathology, demonstrates that beeswax remains at the surgical site indefinitely and may induce an inflammatory response even 10 years after surgery. It also prevents new bone formation and bone union. Once covered with beeswax, a bone does not regenerate — a major problem for a cardiac surgery patient hoping for his cut sternum to heal well.

Water-soluble and completely synthetic in origin, Ostene doesn't increase the risk of infection. It allows the bone to heal without causing an inflammatory response. Unlike beeswax, it is eliminated from the body shortly after surgery and doesn't react with the body's chemistry.


Related Content

News | PACS

February 22, 2024 — aycan, a recognized leader in medical imaging, announced that Enspectra Health used aycan’s PACS ...

Time February 22, 2024
arrow
Feature | HIMSS | Christine Book

February 22, 2024 — With just weeks to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Time February 22, 2024
arrow
News | Teleradiology

February 21, 2024 —Yellowcross Healthcare Commerce, a telemedicine practice management organization, launched a new ...

Time February 21, 2024
arrow
News | Artificial Intelligence

February 22, 2024 — Hartford HealthCare has announced the unveiling of its Center for AI Innovation in Healthcare ...

Time February 21, 2024
arrow
News | Enterprise Imaging

February 20, 2024 —FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time February 20, 2024
arrow
News | PACS

February 16, 2024 — A new cloud-native PACS that features a unique AI-based reporting module has been launched by ...

Time February 16, 2024
arrow
Sponsored Content | Videos | Enterprise Imaging

Clinicians and referring physicians need fast, secure access to both patient data and their diagnostic or viewing tool ...

Time February 15, 2024
arrow
Feature | Enterprise Imaging

The Healthcare Information and Management Systems (HIMSS24) Conference and Exhibition (March 12-14, in Orlando, Fla.) is ...

Time February 14, 2024
arrow
News | Artificial Intelligence

February 8, 2024 — Paige, a global leader in end-to-end digital pathology solutions and clinical Artificial Intelligence ...

Time February 08, 2024
arrow
News | Artificial Intelligence

February 8, 2024 — Siemens Healthineers, a global leader in medical technology and in researching and training ...

Time February 08, 2024
arrow
Subscribe Now